Opposite effects of two thiazolidinediones, ciglitazone and troglitazone, on proteinase-activated receptor-1-triggered prostaglandin E2 release

Toxicology

Volumn 268, Issue 1-2, 2010, Pages 40-45

  Takaoka, Kaori ^a   Sekiguchi, Fumiko ^a   Shigi, Hidenori ^a   Maeda, Yuma ^a   Nishikawa, Hiroyuki ^a   Kawabata, Atsufumi ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Ciglitazone; Cyclooxygenase 2 (COX 2); Peroxisome proliferator activated receptor (PPAR ); Prostaglandin E2 (PGE2); Proteinase activated receptor 1 (PAR1); Troglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROSTAGLANDIN E2; PROTEINASE ACTIVATED RECEPTOR 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TROGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN TARGETING; RAT; STOMACH EPITHELIUM;

ANIMALS; BASE SEQUENCE; CELL LINE; CHROMANS; DINOPROSTONE; DNA PRIMERS; GASTRIC MUCOSA; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RATS; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

RATTUS;

EID: 73749083050     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.11.020     Document Type: Article

References (35)

1. 2. Arthritis Res. Ther. 7 (2005) R1325-R1337
2. Bishop-Bailey D., and Warner T.D. PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J. 17 (2003) 1925-1927
3. Brzozowski T., Konturek P.C., Pajdo R., Kwiecien S.N., Konturek S., Targosz A., Burnat G., Cieszkowski J., Pawlik W.W., and Hahn E.G. Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology 13 (2005) 317-330
4. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (2001) 48-52
5. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P., Leibowitz M.D., Colombel J.F., and Auwerx J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193 (2001) 827-838
6. 2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 (1995) 803-812
7. He Q., Chen J., Lin H.L., Hu P.J., and Chen M.H. Expression of peroxisome proliferator-activated receptor gamma. E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chin. Med. J. 120 (2007) 1498-1504 (Engl)
8. Inoue H., Tanabe T., and Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J. Biol. Chem. 275 (2000) 28028-28032
9. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.W., Timmons C., Tram T., and Coughlin S.R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386 (1997) 502-506
10. Jung J.Y., Yoo C.I., Kim H.T., Kwon C.H., Park J.Y., and Kim Y.K. Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death. Toxicology 234 (2007) 73-82
11. 2 via the phosphatidylinositol 3-kinase and Akt pathway. J. Biol. Chem. 282 (2007) 5356-5366
12. Kawabata A., and Kuroda R. Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. Jpn. J. Pharmacol. 82 (2000) 171-174
13. Kawabata A., Nishikawa H., Saitoh H., Nakaya Y., Hiramatsu K., Kubo S., Nishida M., Kawao N., Kuroda R., Sekiguchi F., Kinoshita M., Kakehi K., Arizono N., Yamagishi H., and Kawai K. A protective role of protease-activated receptor 1 in rat gastric mucosa. Gastroenterology 126 (2004) 208-219
14. Kim S.H., Yoo C.I., Kim H.T., Park J.Y., Kwon C.H., and Kim Y.K. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol. Appl. Pharmacol. 215 (2006) 198-207
15. Konturek P.C., Brzozowski T., Kania J., Konturek S.J., Kwiecien S., Pajdo R., and Hahn E.G. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Eur. J. Pharmacol. 472 (2003) 213-220
16. 2 and troglitazone. J. Clin. Endocrinol. Metab. 87 (2002) 4667-4672
17. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
18. Naito Y., Takagi T., Matsuyama K., Yoshida N., and Yoshikawa T. Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats. Aliment. Pharmacol. Ther. 15 (2001) 865-873
19. Nomura S., Nakajima A., Ishimine S., Matsuhashi N., Kadowaki T., and Kaminishi M. Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. J. Exp. Clin. Cancer Res. 25 (2006) 443-448
20. Nystedt S., Emilsson K., Larsson A.K., Strombeck B., and Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur. J. Biochem. 232 (1995) 84-89
21. Ossovskaya V.S., and Bunnett N.W. Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84 (2004) 579-621
22. Patel K.M., Wright K.L., Whittaker P., Chakravarty P., Watson M.L., and Ward S.G. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma). Cell. Signal. 17 (2005) 1098-1110
23. 2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int. 61 (2002) 1957-1967
24. 2 formation caused by proteinase-activated receptor-1 activation in rat gastric mucosal epithelial cells. Biochem. Pharmacol. 73 (2007) 103-114
25. Sekiguchi F., Takaoka K., and Kawabata A. Proteinase-activated receptors in the gastrointestinal system: a functional linkage to prostanoids. Inflammopharmacology 15 (2007) 246-254
26. Steinhoff M., Buddenkotte J., Shpacovitch V., Rattenholl A., Moormann C., Vergnolle N., Luger T.A., and Hollenberg M.D. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr. Rev. 26 (2005) 1-43
27. 2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J. Biol. Chem. 276 (2001) 48950-48955
28. Tanaka Y., Sekiguchi F., Hong H., and Kawabata A. PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochem. Biophys. Res. Commun. 377 (2008) 622-626
29. Tsukamoto H., Hishinuma T., Suzuki N., Tayama R., Hiratsuka M., Yoshihisa T., Mizugaki M., and Goto J. Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. Prostaglandins Other Lipid Mediat. 73 (2004) 191-213
30. Villegas I., Martin A.R., Toma W., and de la Lastra C.A. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur. J. Pharmacol. 505 (2004) 195-203
31. Vu T.K., Hung D.T., Wheaton V.I., and Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 (1991) 1057-1068
32. Wada K., Nakajima A., Takahashi H., Yoneda M., Fujisawa N., Ohsawa E., Kadowaki T., Kubota N., Terauchi Y., Matsuhashi N., Saubermann L.J., Nakajima N., and Blumberg R.S. Protective effect of endogenous PPARgamma against acute gastric mucosal lesions associated with ischemia-reperfusion. Am. J. Physiol. Gastrointest. Liver Physiol. 287 (2004) G452-G458
33. Willson T.M., Lehmann J.M., and Kliewer S.A. Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann. N.Y. Acad. Sci. 804 (1996) 276-283
34. Xu W.F., Andersen H., Whitmore T.E., Presnell S.R., Yee D.P., Ching A., Gilbert T., Davie E.W., and Foster D.C. Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6642-6646
35. Zingarelli B., and Cook J.A. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23 (2005) 393-399